TCGX Acquisition Corp. — Form 8-K

TCGX Acquisition Corp. entered into a business combination agreement dated October 18, 2026, with TriGemX Bio, Inc. (formerly Kallyope, Inc.) with a pre-money equity value of $361 million. The transaction includes $160 million in PIPE financing at $10.00 per share from investors including TCG Crossover Fund III. Upon closing, Company shareholders will receive TCGX shares based on an exchange ratio calculated from the pre-money valuation and fully-diluted shares. The merger is subject to TCGX shareholder and Company stockholder approval, with sponsor letters and transaction support agreements already in place.